experimental group:Single subcutaneous administration of recombinant human hyaluronidase

2 trials

Sponsors

Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing Chao-Yang Hospital, Capital Medical University

Conditions

Facilitating Diffusion of Subcutaneous InjectionPromote the diffusion of subcutaneous infusion to replace intravenous infusion

Phase 1

Clinical Study for Safety, Tolerance, Pharmacokinetics and Immunogenicity of Single Administration of Recombinant Human Hyaluronidase for Injection in Chinese Healthy Volunteers

RecruitingChiCTR1900026052

Beijing Tongren Hospital Affiliated to Capital Medical UniversityFacilitating Diffusion of Subcutaneous Injection

Start: 2019-09-25Updated: 2019-09-30

Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of recombinant human hyaluronidase injection (ZG096) in healthy Chinese subjects after single dose administration

Active, not recruitingChiCTR2500103454

Beijing Chao-Yang Hospital, Capital Medical UniversityPromote the diffusion of subcutaneous infusion to replace intravenous infusion

Start: 2025-06-06Updated: 2025-06-02